Heme
Advertisement
MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.
Mice treated with the novel approach had a “significantly lower tumor burden” compared with mice that received controls.
The two specific combinations recently approved by the MHRA in the UK also have a BLA currently under review at the FDA.
The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.